Delayed diagnosis of mucopolysaccharidosis type I in a patient with spinopelvic instability, short stature, and skeletal dysplasia
Open Access
- 10 April 2026
- journal article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (6)
Abstract
Pathogenic variants in IDUA, encoding α-L-iduronidase (IDUA), cause the autosomal recessive lysosomal storage disorder mucopolysaccharidosis type I (MPS I). Deficiency of α-L-iduronidase leads to the accumulation of partially degraded glycosaminoglycans in various tissues, including the musculoskeletal system. Clinically, typical skeletal manifestations are dysostosis multiplex, joint contractures, and low BMD. Mucopolysaccharidosis type I represents a spectrum of disease severity. Especially in attenuated disease, establishing an accurate diagnosis and initiating disease-specific therapy, including enzyme replacement therapy (ERT) and osteological treatment, is challenging. A 33-yr-old female patient presented with a history of juvenile idiopathic arthritis, persistent spinopelvic instability, and reduced BMD. Multiple surgical attempts to stabilize the spinopelvic nonunion had failed, thus osteological co-treatment with teriparatide to promote bone healing was recommended. Despite a significant BMD increase, spinopelvic nonunion persisted. Given the combination of short stature, joint contractures, and corneal clouding, a genetic skeletal dysplasia was suspected. Exome sequencing (ES) was inconclusive, whereas short-read genome sequencing (GS) revealed the combination of a 14 kb deletion and a promotor variant in IDUA. Thus, the diagnosis of MPS I in the attenuated form was made, and ERT was initiated. This case highlights the importance of considering MPS I in patients with short stature, joint contractures, skeletal dysplasia, and low BMD. Diagnosis can be overlooked in this attenuated form, underscoring the value of genetic testing, with GS offering advantages over ES. These findings emphasize the need for early diagnosis, systematic osteological evaluation, and individualized treatment strategies in patients with skeletal dysplasia.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft
- Clinical Research Unit CFU 5029
- Precision Medicine for Early-Onset Low Bone Mineral Density Disorders (517063424)
This publication has 20 references indexed in Scilit:
- Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implicationsOrphanet Journal of Rare Diseases, 2018
- Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantationOrphanet Journal of Rare Diseases, 2016
- Altered interaction and distribution of glycosaminoglycans and growth factors in mucopolysaccharidosis type I bone diseaseBone, 2016
- Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibshipsOrphanet Journal of Rare Diseases, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- The natural history of MPS I: global perspectives from the MPS I RegistryGenetics in Medicine, 2014
- Early initiation of enzyme replacement therapy for the mucopolysaccharidosesMolecular Genetics and Metabolism, 2014
- Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidosesOrphanet Journal of Rare Diseases, 2013
- Orthopaedic aspects of mucopolysaccharidosesRheumatology, 2011
- A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 yearsMolecular Genetics and Metabolism, 2007